Switch to:
Also traded in: Austria, Brazil, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 0.54
BIIB's Cash-to-Debt is ranked lower than
87% of the 1078 Companies
in the Global Biotechnology industry.

( Industry Median: 64.02 vs. BIIB: 0.54 )
Ranked among companies with meaningful Cash-to-Debt only.
BIIB' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.25  Med: 2.67 Max: No Debt
Current: 0.54
0.25
No Debt
Equity-to-Asset 0.51
BIIB's Equity-to-Asset is ranked lower than
70% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. BIIB: 0.51 )
Ranked among companies with meaningful Equity-to-Asset only.
BIIB' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.48  Med: 0.76 Max: 0.96
Current: 0.51
0.48
0.96
Debt-to-Equity 0.48
BIIB's Debt-to-Equity is ranked lower than
65% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 0.28 vs. BIIB: 0.48 )
Ranked among companies with meaningful Debt-to-Equity only.
BIIB' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01  Med: 0.13 Max: 0.78
Current: 0.48
0.01
0.78
Debt-to-EBITDA 0.89
BIIB's Debt-to-EBITDA is ranked higher than
68% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 2.04 vs. BIIB: 0.89 )
Ranked among companies with meaningful Debt-to-EBITDA only.
BIIB' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.13  Med: 0.64 Max: 1.2
Current: 0.89
0.13
1.2
Interest Coverage 26.10
BIIB's Interest Coverage is ranked lower than
80% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. BIIB: 26.10 )
Ranked among companies with meaningful Interest Coverage only.
BIIB' s Interest Coverage Range Over the Past 10 Years
Min: 21.56  Med: 43.53 Max: 132.77
Current: 26.1
21.56
132.77
Piotroski F-Score: 7
Altman Z-Score: 6.01
Beneish M-Score: -2.76
WACC vs ROIC
10.57%
21.80%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating Margin % 45.83
BIIB's Operating Margin % is ranked higher than
96% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -113.97 vs. BIIB: 45.83 )
Ranked among companies with meaningful Operating Margin % only.
BIIB' s Operating Margin % Range Over the Past 10 Years
Min: 28.07  Med: 35.59 Max: 49.38
Current: 45.83
28.07
49.38
Net Margin % 23.06
BIIB's Net Margin % is ranked higher than
91% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -111.91 vs. BIIB: 23.06 )
Ranked among companies with meaningful Net Margin % only.
BIIB' s Net Margin % Range Over the Past 10 Years
Min: 19.11  Med: 24.74 Max: 32.95
Current: 23.06
19.11
32.95
ROE % 23.42
BIIB's ROE % is ranked higher than
94% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -42.82 vs. BIIB: 23.42 )
Ranked among companies with meaningful ROE % only.
BIIB' s ROE % Range Over the Past 10 Years
Min: 13.81  Med: 20.75 Max: 35.15
Current: 23.42
13.81
35.15
ROA % 12.52
BIIB's ROA % is ranked higher than
93% of the 1084 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. BIIB: 12.52 )
Ranked among companies with meaningful ROA % only.
BIIB' s ROA % Range Over the Past 10 Years
Min: 9.16  Med: 14.4 Max: 22.42
Current: 12.52
9.16
22.42
ROC (Joel Greenblatt) % 138.46
BIIB's ROC (Joel Greenblatt) % is ranked higher than
96% of the 1036 Companies
in the Global Biotechnology industry.

( Industry Median: -521.46 vs. BIIB: 138.46 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BIIB' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 67.06  Med: 124.23 Max: 214.48
Current: 138.46
67.06
214.48
3-Year Revenue Growth Rate 12.10
BIIB's 3-Year Revenue Growth Rate is ranked higher than
68% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. BIIB: 12.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
BIIB' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -19.4  Med: 20.2 Max: 95.1
Current: 12.1
-19.4
95.1
3-Year EBITDA Growth Rate 15.50
BIIB's 3-Year EBITDA Growth Rate is ranked higher than
64% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. BIIB: 15.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
BIIB' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 25 Max: 127.9
Current: 15.5
0
127.9
3-Year EPS without NRI Growth Rate -1.20
BIIB's 3-Year EPS without NRI Growth Rate is ranked lower than
57% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 5.70 vs. BIIB: -1.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
BIIB' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 25.6 Max: 205.2
Current: -1.2
0
205.2
GuruFocus has detected 1 Warning Sign with Biogen Inc BIIB.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BIIB's 30-Y Financials

Financials (Next Earnings Date: 2018-10-24 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

BIIB Guru Trades in Q3 2017

David Carlson 95,000 sh (New)
Stanley Druckenmiller 48,000 sh (New)
Pioneer Investments 46,690 sh (+77.60%)
Ron Baron 12,951 sh (+0.12%)
John Buckingham 17,073 sh (+0.11%)
Ronald Muhlenkamp 3,000 sh (unchged)
Mairs and Power 1,053 sh (unchged)
Jeremy Grantham 80,000 sh (unchged)
David Dreman 3,705 sh (unchged)
Murray Stahl 4,645 sh (unchged)
John Hussman Sold Out
Lee Ainslie Sold Out
Caxton Associates Sold Out
Jeff Auxier 28,145 sh (-0.09%)
Ken Fisher 107,864 sh (-1.16%)
PRIMECAP Management 15,212,914 sh (-1.16%)
Ray Dalio 44,198 sh (-1.74%)
Vanguard Health Care Fund 3,712,503 sh (-1.91%)
Richard Snow 210,459 sh (-2.19%)
Ronald Muhlenkamp 24,547 sh (-3.91%)
HOTCHKIS & WILEY 274,772 sh (-4.12%)
Mario Gabelli 1,675 sh (-4.29%)
Frank Sands 1,207,172 sh (-5.55%)
Manning & Napier Advisors, Inc 737,735 sh (-9.41%)
Steven Cohen 507,922 sh (-43.06%)
Joel Greenblatt 63,039 sh (-61.20%)
Jim Simons 120,161 sh (-84.25%)
Jeremy Grantham 1,480 sh (-93.96%)
Eaton Vance Worldwide Health Sciences Fund 117,233 sh (-11.72%)
» More
Q4 2017

BIIB Guru Trades in Q4 2017

Richard Pzena 931 sh (New)
Leucadia National 1,537 sh (New)
Caxton Associates 2,866 sh (New)
Paul Tudor Jones 3,354 sh (New)
Pioneer Investments 245,830 sh (+426.52%)
Stanley Druckenmiller 109,400 sh (+127.92%)
Joel Greenblatt 87,874 sh (+39.40%)
Ron Baron 14,868 sh (+14.80%)
John Buckingham 17,300 sh (+1.33%)
Ronald Muhlenkamp 24,682 sh (+0.55%)
Richard Snow 211,462 sh (+0.48%)
Jeff Auxier 28,155 sh (+0.04%)
David Carlson 95,000 sh (unchged)
David Dreman 3,705 sh (unchged)
Murray Stahl 4,645 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 117,233 sh (unchged)
Ray Dalio Sold Out
Jim Simons Sold Out
PRIMECAP Management 15,109,231 sh (-0.68%)
HOTCHKIS & WILEY 271,672 sh (-1.13%)
Mario Gabelli 1,650 sh (-1.49%)
Vanguard Health Care Fund 3,636,003 sh (-2.06%)
Mairs and Power 1,025 sh (-2.66%)
Frank Sands 1,138,777 sh (-5.67%)
Ken Fisher 99,280 sh (-7.96%)
Jeremy Grantham 1,300 sh (-12.16%)
Steven Cohen 252,319 sh (-50.32%)
» More
Q1 2018

BIIB Guru Trades in Q1 2018

John Hussman 10,000 sh (New)
Jim Simons 627,661 sh (New)
Ray Dalio 77,197 sh (New)
Jeremy Grantham 30,200 sh (+2223.08%)
Leucadia National 6,331 sh (+311.91%)
Richard Pzena 1,747 sh (+87.65%)
Steven Cohen 444,615 sh (+76.21%)
Paul Tudor Jones 5,638 sh (+68.10%)
Joel Greenblatt 111,801 sh (+27.23%)
Ken Fisher 123,409 sh (+24.30%)
Ron Baron 17,193 sh (+15.64%)
Richard Snow 237,890 sh (+12.50%)
Ronald Muhlenkamp 25,171 sh (+1.98%)
John Buckingham 17,516 sh (+1.25%)
Jeff Auxier 28,225 sh (+0.25%)
David Carlson 95,000 sh (unchged)
David Dreman 3,705 sh (unchged)
Mairs and Power 1,025 sh (unchged)
Mario Gabelli Sold Out
Frank Sands Sold Out
Stanley Druckenmiller Sold Out
PRIMECAP Management 14,953,231 sh (-1.03%)
Vanguard Health Care Fund 3,592,903 sh (-1.19%)
HOTCHKIS & WILEY 267,672 sh (-1.47%)
Murray Stahl 4,575 sh (-1.51%)
Caxton Associates 2,671 sh (-6.80%)
Pioneer Investments 191,653 sh (-22.04%)
Eaton Vance Worldwide Health Sciences Fund 109,135 sh (-6.91%)
» More
Q2 2018

BIIB Guru Trades in Q2 2018

Leucadia National 12,075 sh (+90.73%)
Paul Tudor Jones 7,591 sh (+34.64%)
Pioneer Investments 201,519 sh (+5.15%)
Ken Fisher 128,113 sh (+3.81%)
Richard Pzena 1,790 sh (+2.46%)
Vanguard Health Care Fund 3,592,903 sh (unchged)
David Carlson 95,000 sh (unchged)
Ronald Muhlenkamp 25,171 sh (unchged)
Murray Stahl 4,575 sh (unchged)
Mairs and Power 1,025 sh (unchged)
Caxton Associates Sold Out
PRIMECAP Management 14,921,936 sh (-0.21%)
Jeff Auxier 28,157 sh (-0.24%)
John Buckingham 17,456 sh (-0.34%)
HOTCHKIS & WILEY 263,072 sh (-1.72%)
Richard Snow 232,465 sh (-2.28%)
Joel Greenblatt 85,107 sh (-23.88%)
Ron Baron 10,085 sh (-41.34%)
Jim Simons 321,500 sh (-48.78%)
John Hussman 5,000 sh (-50.00%)
Steven Cohen 146,000 sh (-67.16%)
Ray Dalio 22,819 sh (-70.44%)
Jeremy Grantham 8,010 sh (-73.48%)
Eaton Vance Worldwide Health Sciences Fund 63,797 sh (-41.54%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:BIIB

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
HOTCHKIS & WILEY 2018-06-30 Reduce -1.72%$257.52 - $306.91 $ 345.2223%263,072
Ken Fisher 2018-06-30 Add 3.81%$257.52 - $306.91 $ 345.2223%128,113
Joel Greenblatt 2018-06-30 Reduce -23.88%0.1%$257.52 - $306.91 $ 345.2223%85,107
Leucadia National 2018-06-30 Add 90.73%0.13%$257.52 - $306.91 $ 345.2223%12,075
Ron Baron 2018-06-30 Reduce -41.34%0.01%$257.52 - $306.91 $ 345.2223%10,085
Richard Pzena 2018-06-30 Add 2.46%$257.52 - $306.91 $ 345.2223%1,790
Vanguard Health Care Fund 2018-03-31 Reduce -1.19%0.03%$260.13 - $367.91 $ 345.2211%3,592,903
HOTCHKIS & WILEY 2018-03-31 Reduce -1.47%$260.13 - $367.91 $ 345.2211%267,672
Ken Fisher 2018-03-31 Add 24.30%0.01%$260.13 - $367.91 $ 345.2211%123,409
Joel Greenblatt 2018-03-31 Add 27.23%0.09%$260.13 - $367.91 $ 345.2211%111,801
Ronald Muhlenkamp 2018-03-31 Add 1.98%0.05%$260.13 - $367.91 $ 345.2211%25,171
Ron Baron 2018-03-31 Add 15.64%$260.13 - $367.91 $ 345.2211%17,193
Leucadia National 2018-03-31 Add 311.91%0.09%$260.13 - $367.91 $ 345.2211%6,331
Richard Pzena 2018-03-31 Add 87.65%$260.13 - $367.91 $ 345.2211%1,747
Mario Gabelli 2018-03-31 Sold Out $260.13 - $367.91 $ 345.2211%0
Vanguard Health Care Fund 2017-12-31 Reduce -2.06%0.05%$307.64 - $344.58 $ 345.228%3,636,003
HOTCHKIS & WILEY 2017-12-31 Reduce -1.13%$307.64 - $344.58 $ 345.228%271,672
Ken Fisher 2017-12-31 Reduce -7.96%$307.64 - $344.58 $ 345.228%99,280
Joel Greenblatt 2017-12-31 Add 39.40%0.12%$307.64 - $344.58 $ 345.228%87,874
Ronald Muhlenkamp 2017-12-31 Add 0.55%0.01%$307.64 - $344.58 $ 345.228%24,682
Ron Baron 2017-12-31 Add 14.80%$307.64 - $344.58 $ 345.228%14,868
Mario Gabelli 2017-12-31 Reduce -1.49%$307.64 - $344.58 $ 345.228%1,650
Leucadia National 2017-12-31 New Buy0.04%$307.64 - $344.58 $ 345.228%1,537
Richard Pzena 2017-12-31 New Buy$307.64 - $344.58 $ 345.228%931
Vanguard Health Care Fund 2017-09-30 Reduce -1.91%0.04%$271.76 - $329.69 $ 345.2217%3,712,503
HOTCHKIS & WILEY 2017-09-30 Reduce -4.12%0.01%$271.76 - $329.69 $ 345.2217%274,772
Ken Fisher 2017-09-30 Reduce -1.16%$271.76 - $329.69 $ 345.2217%107,864
Joel Greenblatt 2017-09-30 Reduce -61.20%0.38%$271.76 - $329.69 $ 345.2217%63,039
Ronald Muhlenkamp 2017-09-30 Reduce -3.91%0.08%$271.76 - $329.69 $ 345.2217%24,547
Ron Baron 2017-09-30 Add 0.12%$271.76 - $329.69 $ 345.2217%12,951
Mario Gabelli 2017-09-30 Reduce -4.29%$271.76 - $329.69 $ 345.2217%1,675
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:ASX:CSL, LSE:SHP, NAS:CELG, NAS:VRTX, NAS:REGN, XKRX:068270, XKRX:207940, NAS:ALXN, NAS:GILD, HKSE:01177, XMCE:GRF.P, NAS:BMRN, XBRU:UCB, NAS:NKTR, OCSE:NZYM B, NAS:INCY, OCSE:GEN, NAS:BIVV, HKSE:02269, NAS:JUNO » details
Traded in other countries:BIIB.Austria, BIIB34.Brazil, IDP.Germany, BIIB.Mexico, BIIB.Switzerland, 0R1B.UK,
Headquarter Location:USA
Biogen Inc is a biopharmaceutical company. It is engaged in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurological, rare and autoimmune diseases.

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen markets novel MS drugs Tysabri and Tecfidera independently. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis.

Guru Investment Theses on Biogen Inc

Jeff Auxier Comments on Biogen - Aug 09, 2018

Biogen (NASDAQ:BIIB)



Biogen saw revenues increase by 9% to $3.4 billion. Revenue growth was driven by Spinal Muscular Atrophy drug Spinraza which saw a 108% increase in revenue. Spinraza is Biogen’s fastest growing drug which they hope will be able to offset the slowing Multiple Sclerosis product line. Biogen presented the detailed results for the phase II trials of their Alzheimer’s drug BAN2401 on July 25th. The results of the trial were positive with tested patients showing 30% less cognitive decline over 18 months than those who received the placebo, but the presentation garnered a mixed reception and caused Biogen’s stock to fall 9% in after-hours trading. Earlier in July, Biogen announced that the trials of the drug were looking very positive without giving any details, and this announcement may have caused many to anticipate that the results would be better than what was ultimately shown. Currently, Biogen’s stock is hurting from the results announcement, but their outlook is still positive in the long-run due to the strength of their pipeline. Another Alzheimer’s drug in Biogen’s pipeline, Aducanumab, just finished its enrollment for two phase III trials. This drug has been regarded as more promising than BAN2401, and if it is successful Biogen will have the only drug in a $12 billion market.

From Jeff Auxier (Trades, Portfolio)'s second quarter 2018 shareholder letter.

Check out Jeff Auxier latest stock trades

Jeff Auxier Comments on Biogen Inc. - May 07, 2018

Biogen Inc. (NASDAQ:BIIB)



On February 15, 2018, Merck discontinued a phase 3 trial of their BACE1 inhibitor, verubecestat, adding the potential Alzheimer’s treatment to a growing list of clinical failures from pharmaceutical companies. This shook investor confidence in Biogen who also has a BACE1 inhibitor currently in late-stage testing. However, Biogen’s leading Alzheimer’s candidate, aducanumab, takes a different approach than BACE1 inhibitors by reducing amyloid plaques in the brain vs. preventing the build-up. Biogen’s expansion by 510 patients in aducanumab’s late-stage study to confront the high variability in the primary endpoint has increased fears of another industry failure. With earnings over $22 this year the stock seems very cheap.



From Jeff Auxier (Trades, Portfolio)'s first-quarter 2018 shareholder letter.

Check out Jeff Auxier latest stock trades

Top Ranked Articles about Biogen Inc

Jeff Auxier Comments on Biogen Guru stock highlight
New Research Coverage Highlights Texas Instruments, Biogen, Sanchez Energy, Amazon, Sirius XM, and JPMorgan Chase — Consolidated Revenues, Company Growth, and Expectations for 2018
Eisai And Biogen Announce Detailed Results Of Phase II Clinical Study Of BAN2401 In Early Alzheimer's Disease At Alzheimer's Association International Conference (AAIC) 2018
Eisai and Biogen Announce Detailed Results of Phase II Clinical Study of BAN2401 in Early Alzheimer’s Disease at Alzheimer’s Association International Conference (AAIC) 2018
Eisai And Biogen Present Detailed Results From Phase II Clinical Study Of Elenbecestat In MCI And Mild To Moderate Alzheimer's Disease At Alzheimer's Association International Conference (AAIC) 2018
Eisai and Biogen Present Detailed Results From Phase II Clinical Study of Elenbecestat in MCI and Mild to Moderate Alzheimer’s Disease at Alzheimer’s Association International Conference (AAIC) 2018
US Stocks Green Tuesday Biogen moves on quarterly results
Global markets advanced in morning trading Tuesday, ahead of solid corporate earnings driving markets higher. Read more...
Alzheimer's Disease: Positive Results Lift All Stock Prices The results of Biogen's drug candidate BAN2401 did not just lift its own stock price, but that of its main competitor as well
On July 5, Biogen (BIIB) and Eisai (ESALY) announced positive topline results of BAN2401, a drug candidate for the treatment of Alzheimer's disease. This is significant because it further secures Biogen’s dominance in the Alzheimer's disease space. Read more...
AGTC Treats First Patient of Second Cohort in Phase 1/2 Clinical XLRP Study; Earns $10 Million Enrollment Milestone
AbbVie Authorizes US Sale of Humira Biosimilar Mylan signs license with AbbVie on proposed biosimilar
AbbVie Inc. (NYSE:ABBV) has authorized Mylan NV (NASDAQ:MYL) to market a proposed biosimilar of Humira in the U.S. and other non-European countries. Read more...

Ratios

vs
industry
vs
history
PE Ratio 24.41
BIIB's PE Ratio is ranked higher than
56% of the 248 Companies
in the Global Biotechnology industry.

( Industry Median: 28.79 vs. BIIB: 24.41 )
Ranked among companies with meaningful PE Ratio only.
BIIB' s PE Ratio Range Over the Past 10 Years
Min: 10.8  Med: 20.21 Max: 44.78
Current: 24.41
10.8
44.78
Forward PE Ratio 14.12
BIIB's Forward PE Ratio is ranked higher than
75% of the 77 Companies
in the Global Biotechnology industry.

( Industry Median: 28.41 vs. BIIB: 14.12 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 24.41
BIIB's PE Ratio without NRI is ranked higher than
56% of the 243 Companies
in the Global Biotechnology industry.

( Industry Median: 28.64 vs. BIIB: 24.41 )
Ranked among companies with meaningful PE Ratio without NRI only.
BIIB' s PE Ratio without NRI Range Over the Past 10 Years
Min: 10.8  Med: 20.21 Max: 44.51
Current: 24.41
10.8
44.51
Price-to-Owner-Earnings 16.48
BIIB's Price-to-Owner-Earnings is ranked higher than
75% of the 145 Companies
in the Global Biotechnology industry.

( Industry Median: 34.35 vs. BIIB: 16.48 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
BIIB' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 10.03  Med: 21.1 Max: 60.46
Current: 16.48
10.03
60.46
PB Ratio 5.65
BIIB's PB Ratio is ranked lower than
62% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. BIIB: 5.65 )
Ranked among companies with meaningful PB Ratio only.
BIIB' s PB Ratio Range Over the Past 10 Years
Min: 1.71  Med: 4.69 Max: 8.84
Current: 5.65
1.71
8.84
PS Ratio 5.63
BIIB's PS Ratio is ranked higher than
68% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. BIIB: 5.63 )
Ranked among companies with meaningful PS Ratio only.
BIIB' s PS Ratio Range Over the Past 10 Years
Min: 2.58  Med: 5.23 Max: 10.99
Current: 5.63
2.58
10.99
Price-to-Free-Cash-Flow 15.64
BIIB's Price-to-Free-Cash-Flow is ranked higher than
78% of the 152 Companies
in the Global Biotechnology industry.

( Industry Median: 37.07 vs. BIIB: 15.64 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
BIIB' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 9.25  Med: 17.77 Max: 36.13
Current: 15.64
9.25
36.13
Price-to-Operating-Cash-Flow 12.74
BIIB's Price-to-Operating-Cash-Flow is ranked higher than
81% of the 210 Companies
in the Global Biotechnology industry.

( Industry Median: 29.99 vs. BIIB: 12.74 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
BIIB' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 7.22  Med: 15.11 Max: 32.48
Current: 12.74
7.22
32.48
EV-to-EBIT 12.24
BIIB's EV-to-EBIT is ranked higher than
70% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.17 vs. BIIB: 12.24 )
Ranked among companies with meaningful EV-to-EBIT only.
BIIB' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.5  Med: 13.75 Max: 30
Current: 12.24
7.5
30
EV-to-EBITDA 10.82
BIIB's EV-to-EBITDA is ranked higher than
69% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.08 vs. BIIB: 10.82 )
Ranked among companies with meaningful EV-to-EBITDA only.
BIIB' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.1  Med: 11.35 Max: 24.8
Current: 10.82
6.1
24.8
EV-to-Revenue 5.61
BIIB's EV-to-Revenue is ranked higher than
71% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 13.69 vs. BIIB: 5.61 )
Ranked among companies with meaningful EV-to-Revenue only.
BIIB' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.5  Med: 5.3 Max: 10.9
Current: 5.61
2.5
10.9
PEG Ratio 0.91
BIIB's PEG Ratio is ranked higher than
72% of the 115 Companies
in the Global Biotechnology industry.

( Industry Median: 2.02 vs. BIIB: 0.91 )
Ranked among companies with meaningful PEG Ratio only.
BIIB' s PEG Ratio Range Over the Past 10 Years
Min: 0.31  Med: 0.76 Max: 3.42
Current: 0.91
0.31
3.42
Shiller PE Ratio 34.55
BIIB's Shiller PE Ratio is ranked higher than
59% of the 86 Companies
in the Global Biotechnology industry.

( Industry Median: 42.91 vs. BIIB: 34.55 )
Ranked among companies with meaningful Shiller PE Ratio only.
BIIB' s Shiller PE Ratio Range Over the Past 10 Years
Min: 26.95  Med: 72.72 Max: 492.6
Current: 34.55
26.95
492.6
Current Ratio 2.36
BIIB's Current Ratio is ranked lower than
70% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. BIIB: 2.36 )
Ranked among companies with meaningful Current Ratio only.
BIIB' s Current Ratio Range Over the Past 10 Years
Min: 0.78  Med: 3.94 Max: 20.41
Current: 2.36
0.78
20.41
Quick Ratio 2.06
BIIB's Quick Ratio is ranked lower than
71% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.18 vs. BIIB: 2.06 )
Ranked among companies with meaningful Quick Ratio only.
BIIB' s Quick Ratio Range Over the Past 10 Years
Min: 0.7  Med: 3.55 Max: 20.41
Current: 2.06
0.7
20.41
Days Inventory 195.18
BIIB's Days Inventory is ranked lower than
70% of the 481 Companies
in the Global Biotechnology industry.

( Industry Median: 125.55 vs. BIIB: 195.18 )
Ranked among companies with meaningful Days Inventory only.
BIIB' s Days Inventory Range Over the Past 10 Years
Min: 195.18  Med: 238.11 Max: 266.3
Current: 195.18
195.18
266.3
Days Sales Outstanding 68.99
BIIB's Days Sales Outstanding is ranked lower than
54% of the 668 Companies
in the Global Biotechnology industry.

( Industry Median: 64.17 vs. BIIB: 68.99 )
Ranked among companies with meaningful Days Sales Outstanding only.
BIIB' s Days Sales Outstanding Range Over the Past 10 Years
Min: 39.79  Med: 46.41 Max: 68.99
Current: 68.99
39.79
68.99
Days Payable 61.81
BIIB's Days Payable is ranked lower than
51% of the 536 Companies
in the Global Biotechnology industry.

( Industry Median: 63.91 vs. BIIB: 61.81 )
Ranked among companies with meaningful Days Payable only.
BIIB' s Days Payable Range Over the Past 10 Years
Min: 61.81  Med: 95.56 Max: 148.21
Current: 61.81
61.81
148.21

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 3.40
BIIB's 3-Year Average Share Buyback Ratio is ranked higher than
99% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -13.40 vs. BIIB: 3.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BIIB' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -92.1  Med: 0.6 Max: 30.9
Current: 3.4
-92.1
30.9

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 20.28
BIIB's Price-to-Tangible-Book is ranked lower than
89% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 5.32 vs. BIIB: 20.28 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
BIIB' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.07  Med: 5.03 Max: 24.42
Current: 20.28
0.07
24.42
Price-to-Intrinsic-Value-Projected-FCF 1.59
BIIB's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
74% of the 193 Companies
in the Global Biotechnology industry.

( Industry Median: 3.12 vs. BIIB: 1.59 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
BIIB' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.05  Med: 1.63 Max: 12.97
Current: 1.59
0.05
12.97
Price-to-Intrinsic-Value-DCF (Earnings Based) 0.86
BIIB's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
82% of the 38 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. BIIB: 0.86 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
BIIB' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.46  Med: 0.65 Max: 0.99
Current: 0.86
0.46
0.99
Price-to-Median-PS-Value 1.08
BIIB's Price-to-Median-PS-Value is ranked lower than
59% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 0.92 vs. BIIB: 1.08 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BIIB' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.05  Med: 0.96 Max: 13.63
Current: 1.08
0.05
13.63
Price-to-Peter-Lynch-Fair-Value 1.07
BIIB's Price-to-Peter-Lynch-Fair-Value is ranked higher than
67% of the 64 Companies
in the Global Biotechnology industry.

( Industry Median: 1.72 vs. BIIB: 1.07 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
BIIB' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.41  Med: 1.12 Max: 52.27
Current: 1.07
0.41
52.27
Price-to-Graham-Number 4.69
BIIB's Price-to-Graham-Number is ranked lower than
73% of the 200 Companies
in the Global Biotechnology industry.

( Industry Median: 2.27 vs. BIIB: 4.69 )
Ranked among companies with meaningful Price-to-Graham-Number only.
BIIB' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.07  Med: 2.9 Max: 37.13
Current: 4.69
0.07
37.13
Earnings Yield (Greenblatt) % 8.18
BIIB's Earnings Yield (Greenblatt) % is ranked higher than
93% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: -7.73 vs. BIIB: 8.18 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BIIB' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.3  Med: 7.3 Max: 13.4
Current: 8.18
3.3
13.4
Forward Rate of Return (Yacktman) % 23.31
BIIB's Forward Rate of Return (Yacktman) % is ranked higher than
90% of the 135 Companies
in the Global Biotechnology industry.

( Industry Median: 11.41 vs. BIIB: 23.31 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
BIIB' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 14.5  Med: 22.9 Max: 26.9
Current: 23.31
14.5
26.9

More Statistics

Revenue (TTM) (Mil) $12,872.40
EPS (TTM) $ 14.13
Beta1.40
Volatility28.77%
52-Week Range $249.17 - 388.67
Shares Outstanding (Mil)201.44

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 13,174 13,458 13,711
EBIT (Mil $) 6,268 6,723 6,922
EBITDA (Mil $) 6,964 7,341 7,513
EPS ($) 22.23 24.68 25.73
EPS without NRI ($) 22.23 24.68 25.73
EPS Growth Rate
(Future 3Y To 5Y Estimate)
7.22%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 77
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}